One of the most important questions anyone and their families affected by Parkinson’s disease is the prognosis for treatment of the disease.
Parkinson’s disease is a progressive, degenerative neurological disease affecting 1 in 500 people. It is believed that between 7 to 10 million people worldwide are affected and that 60,000 new cases are diagnosed annually in the United States alone.
It results from degeneration of neurons in a region of the brain that controls movement though the specific cause is unknown.
The main pathologic feature of Parkinson’s disease is degeneration of dopaminergic cells in the basal ganglia, especially in the substantia nigra leading to progressive loss of control over movement and speech.
What sets HypGen apart is that we are aiming to TREAT the DISEASE and not just treat the symptoms.
RP-323 stands out as a new class of drug that treats at the cellular level, through differentiation, stem cell activation and apoptosis. Other key features include being one of the most active differentiation agents ever discovered, Targeted Therapy, Immunotherapy and Platform Technology.
HypGen is partnering with a major University Hospital in Atlanta Georgia to conduct clinical trials. The University is one of the leading clinical and research centers for Parkinson’s disease in the United States.
HypGen has completed four clinical studies for safety with 155 patients and are now applying for Phase 1 / 2 trials with the FDA.